Who owns Prime Medicine, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of PRME from SEC Form 13F filings across 186 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 186 institutions disclosed 123.5M shares of Prime Medicine, Inc. worth $377.3M — about 69.4% of shares outstanding; the largest disclosed holder is ARCH Venture Management, LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
186
13F holders
$377.3M
value, 2026 filers
69.4%
of shares outstanding (123.5M sh)
26
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of PRME's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | ARCH Venture Management, LLCNEW | 18.5M | $56.5M | 3.5% | 10.4% | new |
| 2 | Alphabet Inc. | 16.6M | $50.7M | 0.1% | 9.3% | 0.0% |
| 3 | BlackRock, Inc. | 10.7M | $32.7M | 0.0% | 6% | +11.6% |
| 4 | ARK Investment Management LLC | 10.0M | $30.7M | 0.2% | 5.6% | +20.3% |
| 5 | STATE STREET CORP | 6.1M | $18.8M | 0.0% | 3.5% | -18.8% |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 4.6M | $14.0M | 0.0% | 2.6% | +1.3% |
| 7 | T. Rowe Price Investment Management, Inc. | 4.6M | $13.9M | 0.0% | 2.6% | -13.0% |
| 8 | Balyasny Asset Management L.P. | 3.6M | $10.9M | 0.0% | 2% | -10.3% |
| 9 | Casdin Capital, LLC | 3.2M | $9.7M | 0.4% | 1.8% | 0.0% |
| 10 | Woodline Partners LP | 3.0M | $9.2M | 0.0% | 1.7% | +0.1% |
| 11 | Sumitomo Mitsui Trust Group, Inc. | 2.9M | $8.9M | 0.0% | 1.6% | +20.7% |
| 12 | Amova Asset Management Americas, Inc. | 2.9M | $8.9M | 0.1% | 1.6% | +21.0% |
| 13 | GOLDMAN SACHS GROUP INC | 2.8M | $8.7M | 0.0% | 1.6% | -17.3% |
| 14 | GEODE CAPITAL MANAGEMENT, LLC | 2.5M | $7.5M | 0.0% | 1.4% | -9.6% |
| 15 | UBS Group AG | 2.3M | $7.1M | 0.0% | 1.3% | -16.3% |
| 16 | ADAR1 Capital Management, LLC | 1.6M | $4.9M | 0.2% | 0.9% | -20.0% |
| 17 | TWO SIGMA INVESTMENTS, LP | 1.4M | $4.2M | 0.0% | 0.8% | -10.2% |
| 18 | FMR LLC | 1.3M | $4.1M | 0.0% | 0.8% | -24.3% |
| 19 | FARALLON CAPITAL MANAGEMENT, L.L.C. | 1.2M | $3.8M | 0.0% | 0.7% | 0.0% |
| 20 | BANK OF AMERICA CORP /DE/ | 1.2M | $3.7M | 0.0% | 0.7% | +24.1% |
| 21 | Redmile Group, LLC | 1.1M | $3.5M | 0.3% | 0.6% | -17.5% |
| 22 | MILLENNIUM MANAGEMENT LLC | 1.1M | $3.2M | 0.0% | 0.6% | +148.1% |
| 23 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.0M | $3.1M | 0.0% | 0.6% | +10.8% |
| 24 | VANGUARD PORTFOLIO MANAGEMENT LLC | 976,500 | $3.0M | 0.0% | 0.5% | +1.5% |
| 25 | NORTHERN TRUST CORP | 918,224 | $2.8M | 0.0% | 0.5% | +0.6% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.